Genmab A GMAB
NASDAQ GMAB
$54.07 -1.73 (-3.10%)
At close: Nov 10, 2026 · 4:00 PM EST

Genmab A (GMAB) EBITDA Margin (2024 - 2026)

Updated

Genmab A (GMAB) reported EBITDA Margin of 34.72% for the quarter ended Jun 30, 2026, up 11.39 percentage points from the prior quarter.

Analysis

Genmab A (GMAB) EBITDA Margin (2024 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Genmab A's EBITDA Margin came in at 23.59%; for the year ended Dec 31, 2025, it came in at 30.54%, down 2.53 percentage points from the prior year.

  • By year, EBITDA Margin came in at 33.07% in the year ended Dec 31, 2024 (-1.03 pp) and 34.10% in the year ended Dec 31, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 54.65%
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 32.68%
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 46.88%
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 40.75%
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 46.62%
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 50.63%
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 42.49%
10 Genmab A 3.52 Bn -5.55 Bn 1.07 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 38.58%
Jun 30, 2026 34.72%
Mar 31, 2026 23.33%
Mar 31, 2025 28.53%
Mar 31, 2024 21.39%
API Access

Genmab A EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=GMAB&period=max&api_key=YOUR_API_KEY